Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CRCL
MCID: CRT084
MIFTS: 25

Creatinine Clearance Quantitative Trait Locus (CRCL)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards integrated aliases for Creatinine Clearance Quantitative Trait Locus:

Name: Creatinine Clearance Quantitative Trait Locus 56
Creatinine Clearance Qtl 56 13
Crcl 56

External Ids:

OMIM 56 607135
Sources

Summaries for Creatinine Clearance Quantitative Trait Locus

About this section
MalaCards based summary : Creatinine Clearance Quantitative Trait Locus, also known as creatinine clearance qtl, is related to rapidly involuting congenital hemangioma and ovarian cancer. An important gene associated with Creatinine Clearance Quantitative Trait Locus is CRCL (Creatinine Clearance QTL). The drugs Clopidogrel and Valganciclovir have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver.

More information from OMIM: 607135
Sources

Related Diseases for Creatinine Clearance Quantitative Trait Locus

About this section

Diseases related to Creatinine Clearance Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 rapidly involuting congenital hemangioma 10.3
2 ovarian cancer 10.2
3 ataxia and polyneuropathy, adult-onset 10.2
4 chagas disease 10.2
5 mouth disease 10.2
6 pathologic nystagmus 10.2

Graphical network of the top 20 diseases related to Creatinine Clearance Quantitative Trait Locus:



Diseases related to Creatinine Clearance Quantitative Trait Locus
Sources

Symptoms & Phenotypes for Creatinine Clearance Quantitative Trait Locus

About this section

Clinical features from OMIM:

607135
Sources

Drugs & Therapeutics for Creatinine Clearance Quantitative Trait Locus

About this section

Drugs for Creatinine Clearance Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 269)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
3
Fondaparinux Approved, Investigational Phase 4 104993-28-4
4
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
7
Warfarin Approved Phase 4 81-81-2 6691 54678486
8
Rivaroxaban Approved Phase 4 366789-02-8
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Dalteparin Approved Phase 4 9005-49-6
11
Edoxaban Approved Phase 4 480449-70-5
12
Enoxaparin Approved Phase 4 9005-49-6 772
13
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
14
Phylloquinone Approved, Investigational Phase 4 84-80-0
15
Pemetrexed Approved, Investigational Phase 4 137281-23-3, 150399-23-8 60843 446556
16
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
17
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Ketorolac Approved Phase 4 66635-83-4, 74103-06-3 3826
21
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
22
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
23
Acetaminophen Approved Phase 4 103-90-2 1983
24
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
25
Morphine Approved, Investigational Phase 4 57-27-2 5288826
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
28
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
29
Vancomycin Approved Phase 4 1404-90-6 14969 441141
30
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
31
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
32
Fosfomycin Approved Phase 4 23155-02-4 446987
33
Ofloxacin Approved Phase 4 82419-36-1 4583
34
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
35
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
36
Dabigatran Investigational Phase 4 211914-51-1
37 Menaquinone Investigational Phase 4 1182-68-9
38 Cyclooxygenase Inhibitors Phase 4
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4
40 PENTA Phase 4
41 Hematinics Phase 4
42 Ferric Oxide, Saccharated Phase 4
43 Calamus Phase 4
44 Platelet Aggregation Inhibitors Phase 4
45 Antithrombins Phase 4
46 Antithrombin III Phase 4
47 Serine Proteinase Inhibitors Phase 4
48 Factor Xa Inhibitors Phase 4
49 Anticoagulants Phase 4
50 Heparin, Low-Molecular-Weight Phase 4

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
2 Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease Completed NCT01084278 Phase 4 Colchicine
3 Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study Completed NCT00555438 Phase 4 fondaparinux 1.5 mg/day
4 A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy Completed NCT01896297 Phase 4 Pradaxa, dabigatran etexilate
5 Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
6 A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County Completed NCT01781806 Phase 4 emtricitabine 200mg/tenofovir 300mg
7 Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis Completed NCT02864199 Phase 4 Peginterferon alfa-2a;Ribavirin
8 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter Completed NCT01976507 Phase 4 dabigatran etexilate mesylate
9 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study Completed NCT02503982 Phase 4 prophylactic Valganciclovir
10 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study) Completed NCT01417949 Phase 4
11 Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study Completed NCT02392910 Phase 4 Iron Sucrose;Placebo
12 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) Recruiting NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
13 A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease Recruiting NCT03718559 Phase 4 Edoxaban;Single Antiplatelet Agents
14 Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR) Recruiting NCT03607149 Phase 4 Pemetrexed
15 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Recruiting NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
16 Pilot Randomised Controlled Trial of Penicillin Versus Flucloxacillin for Definitive Treatment of Invasive Penicillin Susceptible Staphylococcus Aureus Not yet recruiting NCT03632642 Phase 4 Benzylpenicillin;Flucloxacillin
17 Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty Suspended NCT02219581 Phase 4 Dexamethasone 10 mg;Dexamethasone 20 mg;Standard multimodal pain management regimen;Placebo
18 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
19 Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS) Terminated NCT03697993 Phase 4 Fosfomycin tromethamine;Levofloxacin
20 Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients Terminated NCT01786161 Phase 4 Vancomycin continuous infusion;Vancomycin intermittent dosing interval
21 Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens Terminated NCT01133600 Phase 4 Cubicin;Vancomycin
22 Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients With Type 2 Diabetes Mellitus Withdrawn NCT03042325 Phase 4 Alogliptin
23 To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors Withdrawn NCT03676361 Phase 4 Desmopressin
24 Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin Unknown status NCT03299296 Phase 3 Rivaroxaban 10 Milligrams;Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
25 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
26 Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation Completed NCT00494871 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Warfarin;Rivaroxaban placebo;Warfarin placebo
27 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
28 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
29 An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed NCT01839357 Phase 3 Rivaroxaban (Xarelto, BAY59-7939)
30 A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed NCT01674647 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Vitamin K antagonist (VKA)
31 A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection Recruiting NCT03830333 Phase 3 Ceftolozane/Tazobactam;Metronidazole;Meropenem;Placebo
32 COmbination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1) Recruiting NCT04327791 Phase 2, Phase 3 Baloxavir;Placebos
33 Systemic Anticoagulation With Full Dose Low Molecular Weight Heparin (LMWH) Vs. Prophylactic or Intermediate Dose LMWH in High Risk COVID-19 Patients (HEP-COVID Trial) Recruiting NCT04401293 Phase 3 Enoxaparin;Prophylactic/Intermediate Dose Enoxaparin
34 A Randomized Trial of Anticoagulation Strategies in COVID-19 Recruiting NCT04359277 Phase 3 Enoxaparin Higher Dose;Lower-dose prophylactic anticoagulation
35 Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy Recruiting NCT03869931 Phase 3 Fenofibrate
36 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET Recruiting NCT02618577 Phase 3 Edoxaban;ASA
37 A Randomized, Open Label, Active Control, 2 Parallel Groups, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Balanced Salt Solution Versus 0.9% Saline in Patients With High Risk of Contrast Induced Nephropathy. Recruiting NCT02799368 Phase 3 CJ Plasma Solution A Injection;CJ 0.9% Normal Saline Injection
38 Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus Recruiting NCT03232398 Phase 3 Apixaban Oral Tablet [Eliquis];Warfarin
39 COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
40 A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens Unknown status NCT01502085 Phase 1, Phase 2 Vorinostat, Lenalinomide and Dexamethasone
41 Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Completed NCT02409524 Phase 2
42 Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Completed NCT01222260 Phase 2 Bendamustine;Dexamethasone
43 Phase II Study Designed To Evaluate Safety and Tumor Debulking Mechanism of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck. Completed NCT01998542 Phase 2
44 N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery. Completed NCT00122018 Phase 2 N-acetylcysteine;fenoldopam
45 A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin Completed NCT02321800 Phase 2 Cefiderocol;Imipenem/cilastatin
46 An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure Completed NCT01270932 Phase 2 Lenalidomide and Dexamethasone
47 Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells Completed NCT00923845 Phase 2 Pentostatin;Sirolimus;Cyclophosphamide
48 The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies. Completed NCT00593580 Phase 2 placebo;alendronate/cholecalciferol
49 Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial Completed NCT02347501 Phase 2 Sitagliptin (Januvia)
50 Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. Completed NCT01991197 Phase 2 Sitagliptin;Gliclazide;Sitagliptin matched placebo;Gliclazide matched placebo capsule

Search NIH Clinical Center for Creatinine Clearance Quantitative Trait Locus

Sources

Genetic Tests for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Anatomical Context for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards organs/tissues related to Creatinine Clearance Quantitative Trait Locus:

40
Kidney, Heart, Liver, Lung, Bone, Skin, Testes
Sources

Publications for Creatinine Clearance Quantitative Trait Locus

About this section

Articles related to Creatinine Clearance Quantitative Trait Locus:

(show top 50) (show all 1527)
# Title Authors PMID Year
1
A genome scan for renal function among hypertensives: the HyperGEN study. 56
11115379 2001
2
Predictive ability of creatinine clearance versus estimated glomerular filtration rate for outcomes in patients with non-valvular atrial fibrillation: Subanalysis of the J-RHYTHM Registry. 61
32566722 2020
3
A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment. 61
32567817 2020
4
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. 61
32323191 2020
5
Population Pharmacokinetics and Dosing Recommendations of Levetiracetam in Adult and Elderly Patients With Epilepsy. 61
32113977 2020
6
Computed Tomography Parameters and Estimated Glomerular Filtration Rate Formulas for Peridonation Living Kidney Donor Assessment. 61
32505497 2020
7
Evaluation of the Accuracy of Standard Renal Function Equations in Critically Ill Patients with Subarachnoid Hemorrhage. 61
31591691 2020
8
Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. 61
32493164 2020
9
Association of adverse events and associated cost with efficacy for approved relapsed and/or refractory multiple myeloma regimens: A Bayesian network meta-analysis of phase 3 randomized controlled trials. 61
32154922 2020
10
Population Pharmacokinetics of Piperacillin following Continuous Infusion in Critically Ill Patients and Impact of Renal Function on Target Attainment. 61
32284376 2020
11
Enhancement of the Magnetic Coupling in Exfoliated CrCl3 Crystals Observed by Low-Temperature Magnetic Force Microscopy and X-ray Magnetic Circular Dichroism. 61
32390212 2020
12
Outcomes associated with apixaban vs warfarin in patients with renal dysfunction. 61
32463871 2020
13
The Magnitude of the Warfarin-Amiodarone Drug-Drug Interaction Varies With Renal Function: A Propensity-Matched Cohort Study. 61
32112562 2020
14
A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial. 61
32493475 2020
15
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications. 61
31721053 2020
16
Effect of N-acetylcysteine against Vancomycin-Induced Nephrotoxicity: A Randomized Controlled Clinical Trial. 61
32536177 2020
17
Comparison of Anti-factor Xa Activity Among Three Different Factor Xa Inhibitors in Non-valvular Atrial Fibrillation Patients with Renal Impairment. 61
32314297 2020
18
Exchange Bias in van der Waals CrCl3/Fe3GeTe2 Heterostructures. 61
32463247 2020
19
Average Tibial Plateau Angle of 3,922 Stifles Undergoing Surgical Stabilization for Cranial Cruciate Ligament Rupture. 61
31978937 2020
20
An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines. 61
32476520 2020
21
The effect of body mass index and creatinine clearance on serum trough concentration of vancomycin in adult patients. 61
32404057 2020
22
Pharmacokinetics and pharmacogenetics of high-dose methotrexate in Chinese adult patients with non-Hodgkin lymphoma: a population analysis. 61
32246190 2020
23
Long-term outcome and progression of osteoarthritis in uncomplicated cases of cranial cruciate ligament rupture treated by tibial plateau leveling osteotomy in dogs. 61
32448811 2020
24
Perils of Antithrombotic Transitions: Effect of Oral Factor Xa Inhibitors on the Heparin Antifactor Xa Assay. 61
32433187 2020
25
Resistin concentrations in serum and stifle synovial fluid from normal and cruciate deficient dogs with osteoarthritis. 61
32472596 2020
26
Cyclization of 1,n-Enynes Initiated by the Addition Reaction of gem-Dichromiomethane Reagents to Alkynes. 61
32324419 2020
27
Retrospective analysis of eligibility for denosumab in patients presenting with osteoporotic fractures and renal impairment treated by orthogeriatric service at Middlemore Hospital. 61
32438373 2020
28
Hydrothermal Synthesis and Gas Sensing of Monoclinic MoO3 Nanosheets. 61
32392711 2020
29
Crystal structure of trans-di-chlorido-(1,4,8,11-tetra-aza-cyclo-tetra-decane-κ4N)chromium(III) bis-(form-amide-κO)(1,4,8,11-tetra-aza-cyclo-tetra-decane-κ4N)chromium(III) bis-[tetra-chlorido-zincate(II)]. 61
32431927 2020
30
Chromium and human low-density lipoprotein oxidation. 61
32058272 2020
31
Thermochemical formation of dioxins promoted by chromium chloride: In situ Cr- and Cl-XAFS analysis. 61
31954297 2020
32
Use of Serum Cystatin C versus Creatinine for Estimation of Renal Function and Valganciclovir Dosing in Heart Transplant Recipients. 61
32465124 2020
33
Rivaroxaban Precision Dosing Strategy for Real-World Atrial Fibrillation Patients. 61
32267996 2020
34
Biomechanical Effects of Tibial Plateau Levelling Osteotomy on Joint Instability in Normal Canine Stifles: An In Vitro Study. 61
32283560 2020
35
Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease. 61
32160801 2020
36
Factors Affecting Trough Plasma Dabigatran Concentrations in Patients with Atrial Fibrillation and Chronic Kidney Disease. 61
32215878 2020
37
Effectiveness of Methenamine for UTI Prevention in Older Adults. 61
31694390 2020
38
Chemoselective Cross-Coupling between Two Different and Unactivated C(aryl)-O Bonds Enabled by Chromium Catalysis. 61
32302116 2020
39
Does the conventional dosage of linezolid necessitate therapeutic drug monitoring?-Experience from a prospective observational study. 61
32395537 2020
40
The Successful Evolution of Everolimus Based Immunosuppression (IS) in a Large Lung Transplant (LTx) Cohort: 14 Years Experience. 61
32465403 2020
41
Pharmacokinetic and pharmacodynamic modeling of levetiracetam: investigation of factors affecting the clinical outcome. 61
32208795 2020
42
Persistence of Magnetism in Atomically Thin MnPS3 Crystals. 61
32142288 2020
43
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. 61
32213316 2020
44
Tubular secretion of creatinine and kidney function: an observational study. 61
32228497 2020
45
Population pharmacokinetics of high-dose methotrexate in Chinese pediatric patients with medulloblastoma. 61
32017134 2020
46
Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation. 61
31492970 2020
47
Mechanical exfoliation and layer number identification of single crystal monoclinic CrCl<sub>3</sub>. 61
32150734 2020
48
Performance of Creatinine Clearance and Estimated GFR in Assessing Kidney Function in Living Donor Candidates. 61
31205262 2020
49
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. 61
31911503 2020
50
Chromium(III)-Catalyzed C(sp2)-H Alkynylation, Allylation, and Naphthalenation of Secondary Amides with Trimethylaluminum as Base. 61
32068410 2020
Sources

Variations for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Expression for Creatinine Clearance Quantitative Trait Locus

About this section
Search GEO for disease gene expression data for Creatinine Clearance Quantitative Trait Locus.
Sources

Pathways for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

GO Terms for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Sources for Creatinine Clearance Quantitative Trait Locus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....